Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| GABAergic neuron | 5 studies | 39% ± 10% | |
| epithelial cell | 4 studies | 41% ± 20% | |
| ciliated cell | 4 studies | 26% ± 10% | |
| respiratory goblet cell | 3 studies | 31% ± 11% | |
| glutamatergic neuron | 3 studies | 23% ± 5% | |
| basal cell | 3 studies | 49% ± 21% | |
| interneuron | 3 studies | 36% ± 13% |
Insufficient scRNA-seq data for expression of LYPD6B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 63% | 251.55 | 206 / 328 | 84% | 16.99 | 149 / 178 |
| prostate | 79% | 598.90 | 193 / 245 | 64% | 5.94 | 320 / 502 |
| stomach | 75% | 1626.41 | 268 / 359 | 50% | 7.35 | 142 / 286 |
| bladder | 43% | 600.33 | 9 / 21 | 73% | 26.06 | 370 / 504 |
| breast | 40% | 237.45 | 183 / 459 | 75% | 18.47 | 834 / 1118 |
| ureter | 0% | 0 | 0 / 0 | 100% | 51.00 | 1 / 1 |
| ovary | 2% | 5.53 | 3 / 180 | 98% | 52.45 | 420 / 430 |
| skin | 93% | 3379.48 | 1678 / 1809 | 3% | 0.35 | 13 / 472 |
| esophagus | 14% | 46.73 | 199 / 1445 | 64% | 8.58 | 117 / 183 |
| uterus | 4% | 35.61 | 7 / 170 | 67% | 13.73 | 308 / 459 |
| tonsil | 0% | 0 | 0 / 0 | 71% | 10.05 | 32 / 45 |
| kidney | 58% | 311.63 | 52 / 89 | 8% | 1.78 | 72 / 901 |
| lung | 9% | 37.45 | 53 / 578 | 57% | 10.78 | 656 / 1155 |
| intestine | 1% | 6.85 | 14 / 966 | 50% | 5.62 | 265 / 527 |
| lymph node | 0% | 0 | 0 / 0 | 21% | 2.98 | 6 / 29 |
| spleen | 18% | 57.42 | 43 / 241 | 0% | 0 | 0 / 0 |
| liver | 0% | 0 | 0 / 226 | 15% | 6.84 | 61 / 406 |
| peripheral blood | 12% | 105.55 | 115 / 929 | 0% | 0 | 0 / 0 |
| brain | 9% | 34.59 | 241 / 2642 | 0% | 0.03 | 3 / 705 |
| thymus | 0% | 5.11 | 3 / 653 | 4% | 0.38 | 27 / 605 |
| adrenal gland | 0% | 0 | 0 / 258 | 3% | 1.06 | 7 / 230 |
| adipose | 1% | 4.94 | 7 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 0% | 0.78 | 1 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 0% | 1.30 | 1 / 1335 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| heart | 0% | 0 | 0 / 861 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0098552 | Cellular component | side of membrane |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0030548 | Molecular function | acetylcholine receptor regulator activity |
| Gene name | LYPD6B |
| Protein name | Ly6/PLAUR domain-containing protein 6B LY6/PLAUR domain containing 6B |
| Synonyms | |
| Description | FUNCTION: Likely acts as a modulator of nicotinic acetylcholine receptors (nAChRs) activity . In vitro acts on nAChRs in a subtype- and stoichiometry-dependent manner . Modulates specifically alpha-3(3):beta-4(2) nAChRs by enhancing the sensitivity to ACh, decreasing ACh-induced maximal current response and increasing the rate of desensitization to ACh; has no effect on alpha-7 homomeric nAChRs; modulates alpha-3(2):alpha-5:beta-4(2) nAChRs in the context of CHRNA5/alpha-5 variant Asn-398 but not its wild-type sequence . However, according to another report in vitro it can weakly inhibits alpha-7 nAChRs . . |
| Accessions | ENST00000442722.5 F8WCH4 ENST00000280115.8 Q8NI32 ENST00000409642.8 [Q8NI32-2] H7BXI7 ENST00000409029.5 [Q8NI32-1] ENST00000437627.5 ENST00000409876.5 [Q8NI32-1] F8WB42 F8WEI1 ENST00000450639.5 |
